Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Status Report on COVID-19 Vaccines Development
Arun Kumar, William E. Dowling, Raúl Gómez Román, et al.
Current Infectious Disease Reports (2021) Vol. 23, Iss. 6
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Global COVID-19 Vaccine Acceptance: A Systematic Review of Associated Social and Behavioral Factors
Choudhary Sobhan Shakeel, Amenah Abdul Mujeeb, Muhammad Shaheer Mirza, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 110-110
Open Access | Times Cited: 141
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Saeed Khoshnood, Maniya Arshadi, Sousan Akrami, et al.
Journal of Clinical Laboratory Analysis (2022) Vol. 36, Iss. 5
Open Access | Times Cited: 65
Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles
Anna Piperno, Maria Teresa Sciortino, Elena Giusto, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 5981-6002
Open Access | Times Cited: 60
Lactoferrin for COVID-19 prevention, treatment, and recovery
Ecem Bolat, Furkan Eker, Merve Kaplan, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 39
Development and applications of mRNA treatment based on lipid nanoparticles
Zhe Wang, Wanting Ma, Xingxing Fu, et al.
Biotechnology Advances (2023) Vol. 65, pp. 108130-108130
Closed Access | Times Cited: 29
Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis
Mark Manak, Luc Gagnon, Steven Phay-Tran, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 3, pp. e216-e225
Open Access | Times Cited: 8
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design
Daniel Ellis, Natalie Brunette, Katharine H. D. Crawford, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 45
A Comprehensive Overview on COVID-19: Future Perspectives
Rashmi Rana, Ankit Tripathi, Naveen Kumar, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 42
O CAMPO DE PODER DAS VACINAS NA PANDEMIA DA COVID-19
Elói Martins Senhoras
Boletim de Conjuntura (BOCA) (2021) Vol. 6, Iss. 18, pp. 110-121
Closed Access | Times Cited: 41
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Armina Alagheband Bahrami, Ali Azargoonjahromi, Samin Sadraei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 27
Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions
E. Alperay Tarim, Müge Anıl-İnevi, Ilayda Ozkan, et al.
Biomedical Microdevices (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 15
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
Isabella Zanella, Daniela Zizioli, Francesco Castelli, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 5, pp. 454-454
Open Access | Times Cited: 38
Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients
Fanfan Zeng, Mengjun Wu, Jinbiao Wang, et al.
Journal of Medical Virology (2021) Vol. 93, Iss. 12, pp. 6506-6511
Open Access | Times Cited: 37
Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies.

Zhōnghuá mínguó xīnzàngxué huì zázhì (2021) Vol. 37, Iss. 4, pp. 355-364
Closed Access | Times Cited: 37
Viral Glycoproteins Induce NLRP3 Inflammasome Activation and Pyroptosis in Macrophages
Hannah S. Eisfeld, Alexander Simonis, Sandra Winter, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 2076-2076
Open Access | Times Cited: 32
Inactivated vaccine Covaxin/BBV152: A systematic review
Tousief Irshad Ahmed, Saqib Rishi, Summaiya Irshad, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Yasser Mohamed, Yousra A. El‐Maradny, Ahmed K. Saleh, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113499-113499
Open Access | Times Cited: 22
Role of milk glycome in prevention, treatment, and recovery of COVID-19
Merve Kaplan, Arif Sercan Şahutoğlu, Sümeyye Sarıtaş, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 22
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
Faizan Zarreen Simnani, Dibyangshee Singh, Ramneet Kaur
3 Biotech (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 31
The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
Jiezhong Chen, Luis Vitetta, Jeremy D. Henson, et al.
Journal of Functional Foods (2021) Vol. 87, pp. 104850-104850
Open Access | Times Cited: 30
The Spike of SARS-CoV-2: Uniqueness and Applications
Ranjith Kumavath, Debmalya Barh, Bruno Andrade, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 27
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
Kevin R. Bewley, Karen E. Gooch, Kelly Thomas, et al.
Science Advances (2021) Vol. 7, Iss. 37
Open Access | Times Cited: 25
Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates
Alireza Hassani Najafabadi, Zeynab Izadi Najaf Abadi, Marisa Aikins, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 168-178
Open Access | Times Cited: 23
Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
Ki-Back Chu, Hae-Ji Kang, Keon-Woong Yoon, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 920-920
Open Access | Times Cited: 22
Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection
Bedanta Bhattacharjee, Damanbhalang Rynjah, Abdul Baquee Ahmed, et al.
Chemical Papers (2024) Vol. 78, Iss. 4, pp. 2123-2154
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top